RAPT Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 – RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage biopharmaceutical company, announced that President and CEO Brian Wong, M.D., Ph.D., will present at the 40th Annual J.P. Morgan Healthcare Conference. The event will take place on January 11, 2022, at 9:00 a.m. ET. RAPT focuses on developing oral small molecule therapies for inflammatory diseases and oncology. The company has advanced drug candidates RPT193 and FLX475, targeting CCR4 for treating inflammation and cancer. Access the presentation via the RAPT website.

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that Brian Wong, M.D., Ph.D., President and CEO, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 9:00 a.m. ET.

To access the live webcast or subsequent archived recording of the company presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.

About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, RPT193 and FLX475, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.

RAPT Media Contact:
Aljanae Reynolds
areynolds@wheelhouselsa.com

RAPT Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com

FAQ

When is RAPT Therapeutics presenting at the J.P. Morgan Healthcare Conference?

RAPT Therapeutics will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 9:00 a.m. ET.

Who is presenting for RAPT Therapeutics at the healthcare conference?

Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics, will be presenting.

What is the main focus of RAPT Therapeutics?

RAPT Therapeutics focuses on developing oral small molecule therapies for patients with inflammatory diseases and oncology.

What are the drug candidates being developed by RAPT Therapeutics?

RAPT Therapeutics has advanced drug candidates RPT193 and FLX475, targeting CCR4 for treating inflammation and cancer.

How can I access the RAPT Therapeutics presentation?

You can access the live webcast or archived recording of the presentation on the RAPT Therapeutics website.